SCHEMBL3405186

SCHEMBL3405186

CCOC(CCCNc1nc(Cl)nc(N2CCOCC2)c1[N+](=O)[O-])OCC

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.41
MEN1 O00255 3/20 0.41
ALDH1A1 P00352 4/20 0.39
MAPT P10636 8/20 0.37
MAPK1 P28482 3/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
TSHR P16473 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MGMT P16455 1/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
MCL1 Q07820 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3400747 0.83 CTSK (0.43) ALDH1A1MAPK1KDM4ESMN1; SMN2TSHR
SCHEMBL3399391 0.82 ALDH1A1 (0.47) KMT2AMEN1ALDH1A1MAPTMAPK1
SCHEMBL3402065 0.81 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1MAPTMAPK1
SCHEMBL3404172 0.80 MAPT (0.48) ALDH1A1MAPTMAPK1KDM4ELMNA
SCHEMBL3403998 0.78 ALDH1A1 (0.44) KMT2AMEN1ALDH1A1MAPTMAPK1
SCHEMBL3425360 0.77 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1MAPTMAPK1
SCHEMBL3402400 0.76 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1MAPTMAPK1
SCHEMBL3401385 0.75 ALDH1A1 (0.42) KMT2AMEN1ALDH1A1MAPTMAPK1
SCHEMBL3407918 0.72 ACKR3 (0.41) ALDH1A1MAPTSMN1; SMN2LMNA
SCHEMBL11833197 0.72 ALDH1A1 (0.50) KMT2AMEN1ALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102014914-A 3H-[1,2,3]triazolo[4,5-D]pyrimidine compounds, their use as MTOR kinase and PI3 kinase inhibitors, and their syntheses WYETH CORP 2011-04-13 CN disclosed
EP-2252296-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2010-11-24 EP disclosed
WO-2009091788-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-23 WO disclosed
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181963-A1 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, PIK3CA, PIK3CD KMT2A 2952/4885MEN1 1774/4885ALDH1A1 3181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.